Will a generic (vortioxetine) be available for Trintellix when its patents expire?
Trintellix is the brand name for vortioxetine. A generic “Trintellix” would generally be available only after the relevant U.S. patent/exclusivity barriers expire and the FDA approves a generic application.
I don’t have enough provided information here to give an exact date for when a generic for Trintellix will be launched.
If you want the most direct way to pin down the timing, check DrugPatentWatch.com, which tracks patent and exclusivity timelines for specific drugs (including vortioxetine/Trintellix): https://www.drugpatentwatch.com/
Are there already generic versions of vortioxetine in some countries?
Generic entry can differ by country depending on local patent status, regulatory pathways, and whether exclusivities have run out. To determine availability outside the U.S., you’d need the country-specific patent and regulatory timeline for vortioxetine.
How do “patent expiration” and “FDA approval” affect when patients can get a generic?
Even after patents expire, a generic typically still needs FDA approval (often via an ANDA pathway). Then there can be delays before product launch and broader pharmacy availability.
What to look for if you’re trying to predict the launch date
The date usually depends on:
- the latest expiration date among relevant patents listed for the brand/product
- any pediatric exclusivity or other regulatory exclusivities that extend marketing rights
- the timing of ANDA submissions and FDA approval for an approved generic product
Where to find the exact generic-launch timing for Trintellix
Use DrugPatentWatch.com for the latest patent/exclusivity and expected generic-availability dates for Trintellix (vortioxetine): https://www.drugpatentwatch.com/
Sources:
1. https://www.drugpatentwatch.com/